New Trial Data on Childhood Bone Condition Published in Leading Medical Journal

The New England Journal of Medicine has shared findings from the PROPEL 3 phase 3 clinical trial examining an oral treatment for achondroplasia in children, according to a post on the journal’s official social media account.

What the Trial Is About

The New England Journal of Medicine — one of the world’s most cited peer-reviewed medical publications — posted details of a phase 3 clinical trial investigating infigratinib, an oral drug being tested in children with achondroplasia, a genetic condition that affects bone growth and is the most common cause of short stature in children.

Achondroplasia occurs when a mutation in the FGFR3 gene disrupts normal bone development, resulting in shorter limbs relative to the trunk. It affects roughly one in every 25,000 live births, according to NHS genetic health guidance.

The trial — known as PROPEL 3 — is a phase 3 study, meaning it represents one of the later and larger stages of clinical testing before a treatment can be considered for regulatory approval. Phase 3 trials typically compare a new treatment against a placebo or existing standard of care across a broader patient group to assess both effectiveness and safety.

Why Oral Treatment Matters

What makes infigratinib notable in this context is its form. It’s taken orally — as a tablet or liquid — rather than by injection. Current treatments for achondroplasia that have reached advanced trial stages, such as vosoritide, are administered by daily subcutaneous injection. An oral alternative, if proven safe and effective, could represent a meaningful practical difference for children and families managing the condition day to day.

The journal’s post was shared under the hashtag #ICCBH2026, which refers to the International Conference on Children’s Bone Health — a specialist gathering where research into paediatric skeletal conditions is regularly presented and discussed.

The State of the Evidence

It’s worth being clear about what this announcement does and doesn’t tell us. The post links to the published trial article but does not summarise the outcomes. The full findings — including whether infigratinib met its primary endpoints, what side effects were recorded, and how it compared to existing options — are contained within the journal article itself, which is subject to the NEJM’s access terms.

No regulatory decision, NHS approval, or clinical guideline change has been announced in connection with this trial at this stage.

Unanswered Questions

Several questions remain open. It is not yet clear whether the Medicines and Healthcare products Regulatory Agency (MHRA) has received or is reviewing a licence application for infigratinib in this indication. Equally, no position from NHS England or the National Institute for Health and Care Excellence (NICE) on potential approval or commissioning has been published at the time of writing.

—

Key Takeaways

• The NEJM has published findings from the PROPEL 3 phase 3 trial of oral infigratinib in children with achondroplasia, a genetic bone growth condition
• Infigratinib is taken orally, which distinguishes it from injection-based treatments currently used or in development for the same condition
• No regulatory approval, NHS commissioning decision, or NICE guidance has been issued in connection with this trial at this stage

What This Means for Kent Residents

Families in Kent whose children have been diagnosed with achondroplasia should speak to their NHS paediatrician or specialist consultant if they have questions about emerging treatments — this trial represents research progress, not a change in currently available NHS care. Kent and Medway NHS services follow national NICE guidelines and MHRA approvals before new treatments are offered, so any future availability would depend on those regulatory steps being completed first. Parents seeking general guidance can contact their GP, call NHS 111, or in an urgent situation dial 999; the charity Restricted Growth Association UK also provides support and information for families affected by achondroplasia and similar conditions.